Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPACT: Rifaximin and SIMBA Capsule in IBS
NCT07882953Phase 1Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of rifaximin in irritable bowel syndrome (IBS) (3 arms), sponsored by University of Calgary. Primary endpoint: Change in small intestinal microbiome composition. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT07882953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882953.